Scientific split - the human genome breakthrough dividing former colleagues

Two groups are racing to establish scientific and commercial priority over the discovery of the decade

Science Editor

The money men have moved in on a new technique for editing the human genome that promises to revolutionise the way many human diseases will be treated in the future. But Big Money has in the process divided a scientific community into two competing camps.

Some might see it has healthy scientific rivalry spilling over into commercial competition which could ultimately speed up medical innovation. But behind closed doors there is a desperate race to establish scientific and commercial priority over what could be the scientific discovery – and intellectual property – of the decade.

On the one side is a consortium of world-class researchers led by French-born Professor Emmanuelle Charpentier who made a key discovery behind the Crispr gene editing technique and has been promised $25m (£16m) by a group of venture capitalists to commercialise her invention for medical use.

On the other side is her former colleague and the co-discoverer of the gene-editing process, Professor Jennifer Doudna of the University of California, Berkeley, who has joined a rival consortium of researchers with $43m in venture capital to advance the Crispr technique into the clinic.

Each group has recruited a formidable panel of senior scientists as advisers. The Charpentier team, called Crispr Therapeutics, includes Nobel Laureate Craig Mello, the co-discoverer of a gene-silencing technique known as RNAi, and Daniel Anderson of the Massachusetts Institute of Technology, who was the first person to show that Crispr can cure a genetic disease in an adult animal.

Meanwhile the Doudna team, known as Editas Medicine, includes the Harvard geneticist George Church, a pioneer in synthetic biology, and Feng Zhang of MIT and the Broad Institute, who successfully managed to get Crispr to work in human cells and was this month awarded the first US patent on the technique – much to the dismay of Professor Charpentier.

“I have to be careful what I say here. It is very surprising. But the fundamental discovery comes from my laboratory and no-one has told me that they have scooped me,” Professor Charpentier told The Independent.

“Be certain that this discovery did not happen only by chance. I have been thinking, defending and carrying this study from Austria to Sweden and now Germany,” she said.

Patent attorneys are now pouring over the rival patent applications, in particular the claims relating to who has priority over a key element of the Crispr technique called Cas9, a bacterial gene for an enzyme that snips both strands of the DNA double helix at the same place – a key feature of the gene-editing process.

Professor Charpentier said that she identified Cas9, the most important fundamental discovery behind Crispr (pronounced “crisper”), when she worked at Umea University in Sweden, before she had teamed up with Professor Doudna to co-author a scientific paper on Crispr-Cas9 published in August 2012 in the journal Science.

Professor Charpentier, who is now at the Hannover Medical School in Germany, said that Cas9 was in fact described for the first time in an earlier scientific paper, published in Nature in March 2011, under its former name of Csn1, which she had isolated from the bacterium Steptococcus pyogenes.

“I was the scientist who described the technology and I kept the intellectual property when I was in Sweden….Editas does not have access to the intellectual property of the patent where I’m the co-inventor,” Professor Charpentier said.

“I made the decision to do something in Europe and I made the decision not to do something with Editas Medicine. I’m trying to remain true to myself….The aim is to use Crispr-Cas9 as a kind of genetic medicine to treat serious diseases. The point about Cas9 is that it works in every cell and in every organism tested – it’s mind blowing,” she said.

For her part, Professor Doudna said there is room for both camps to develop new medical therapies based on Crispr-Cas9.

“Emmanuelle and I are excited to see this platform employed to help patients, and there are of course many different targets and strategies to be taken, providing opportunities for multiple companies in this space,” Professor Doudna said.

“In addition to start-ups, many existing companies are also interested in using the technology for various applications that extend beyond human therapeutics. I expect that the commercial landscape will continue to evolve as the technology matures,” she said.

The main barrier to using Crispr-Cas9, however, will be its safe and efficient delivery to the cells and tissues that need the genetic therapy. Professor Mello believes that the first treatments are likely to involve the genetic manipulation of stem cells in the laboratory, before transplantation back into the affected parts of the body.

“Delivery to cells within the context of the whole body, brain or other organ is very difficult and inefficient… This is why Crispr therapies will no doubt be limited for the foreseeable future to applications where stem cells can be modified one, or a few, at a time and then reintroduced after double checking that only the intended change was made,” Professor Mello said.

WHAT IS CRISPR?

The human genome consists of a long sequence of "letters" written in the code of the genetic alphabet - the three billion base-pairs of the DNA molecule. The gene-editing technique known as Crispr-Cas9 is able for the first time to delete or swap any of these letters, right down to changing a single base pair at any designated place in the genome.

Crispr, which stands for clustered regularly interspaced short palindromic repeats, was originally discovered as a kind of immune system in bacteria to defend against invading viruses. Its potential for editing the genomes of animals, including humans, only came with the discovery of the Cas9 gene, an enzyme for cutting both strands of DNA, found in the bacterium Streptococcus pyogenes.

The commercial applications of Crispr, which could extend to treating genetic diseases and cancer, will depend to a great extent on Cas9 and who owns the intellectual property on this part of the invention. This is why patent disputes are likely to focus on who did what and when in terms of the Cas9 discovery. Emmanuelle Charpentier of Hannover Medical School in Germany and Jennifer Doudna of the University of California, Berkeley are both named as co-inventors on one patent.

 

Start your day with The Independent, sign up for daily news emails
Voices
Lucerne’s Hotel Château Gütsch, one of the lots in our Homeless Veterans appeal charity auction
charity appeal
Arts and Entertainment
Tony Hughes (James Nesbitt) after his son Olly disappeared on a family holiday in France
tv
News
people

Jo from Northern Ireland was less than impressed by Russell Brand's attempt to stage a publicity stunt

Sport
Scunthorpe goalkeeper Sam Slocombe (left) is congratulated by winning penalty taker Miguel Llera (right)
football
PROMOTED VIDEO
Arts and Entertainment
The Apprentice candidates Roisin Hogan, Solomon Akhtar, Mark Wright, Bianca Miller, Daniel Lassman
tvReview: But which contestants got the boot?
Life and Style
A woman walks by a pandal art installation entitled 'Mars Mission' with the figure of an astronaut during the Durga Puja festival in Calcutta, India
techHow we’ll investigate the existence of, and maybe move in with, our alien neighbours
Arts and Entertainment
Jim Carrey and Jeff Daniels ride again in Dumb and Dumber To
filmReview: Dumb And Dumber To was a really stupid idea
Arts and Entertainment
Sir Ian McKellen tempts the Cookie Monster
tvSir Ian McKellen joins the Cookie Monster for a lesson on temptation
News
i100
Travel
Tourists bask in the sun beneath the skyscrapers of Dubai
travelBritish embassy uses social media campaign to issue travel advice for festive holiday-makers in UAE
News
ebooksNow available in paperback
Arts and Entertainment
Jennifer Saunders stars as Miss Windsor, Dennis's hysterical French teacher
filmJennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress
Life and Style
tech
Sport
Nabil Bentaleb (centre) celebrates putting Tottenham ahead
footballTottenham 4 Newcastle 0: Spurs fans dreaming of Wembley final after dominant win
Voices
Jimmy Mubenga died after being restrained on an aircraft by G4S escorts
voicesJonathan Cox: Tragedy of Jimmy Mubenga highlights lack of dignity shown to migrants
Life and Style
Sebastian Siemiatkowski is the 33-year-old co-founder and CEO of Klarna, which provides a simple way for people to buy things online
tech
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Ashdown Group: Helpdesk Analyst

£25000 per annum: Ashdown Group: An established media firm based in Surrey is ...

Ashdown Group: Java Developer - Hertfordshire - £47,000 + bonus + benefits

£40000 - £470000 per annum + bonus: Ashdown Group: Java Developer / J2EE Devel...

Ashdown Group: Head of Finance - Financial Director - London - £70,000

£70000 per annum: Ashdown Group: Head of Finance - Financial Controller - Fina...

Recruitment Genius: Business Development Executive - Nationwide - OTE £65,000

£30000 - £65000 per annum: Recruitment Genius: This small technology business ...

Day In a Page

Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas
La Famille Bélier is being touted as this year's Amelie - so why are many in the deaf community outraged by it?

Deaf community outraged by La Famille Bélier

The new film tells the story of a deaf-mute farming family and is being touted as this year's Amelie
10 best high-end laptops

10 best high-end laptops

From lightweight and zippy devices to gaming beasts, we test the latest in top-spec portable computers
Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

The batsman has grown disillusioned after England’s Ashes debacle and allegations linking him to the Pietersen affair
Susie Wolff: A driving force in battle for equality behind the wheel

Susie Wolff: A driving force in battle for equality behind the wheel

The Williams driver has had plenty of doubters, but hopes she will be judged by her ability in the cockpit
Adam Gemili interview: 'No abs Adam' plans to muscle in on Usain Bolt's turf

'No abs Adam' plans to muscle in on Usain Bolt's turf

After a year touched by tragedy, Adam Gemili wants to become the sixth Briton to run a sub-10sec 100m
Calls for a military mental health 'quality mark'

Homeless Veterans campaign

Expert calls for military mental health 'quality mark'
Racton Man: Analysis shows famous skeleton was a 6ft Bronze Age superman

Meet Racton Man

Analysis shows famous skeleton was a 6ft Bronze Age superman
Garden Bridge: St Paul’s adds to £175m project’s troubled waters

Garden Bridge

St Paul’s adds to £175m project’s troubled waters
Stuff your own Christmas mouse ornament: An evening class in taxidermy with a festive feel

Stuff your own Christmas mouse ornament

An evening class in taxidermy with a festive feel
Joint Enterprise: The legal doctrine which critics say has caused hundreds of miscarriages of justice

Joint Enterprise

The legal doctrine which critics say has caused hundreds of miscarriages of justice
Freud and Eros: Love, Lust and Longing at the Freud Museum: Objects of Desire

Freud and Eros

Love, Lust and Longing at the Freud Museum